Purchase this article with an account.
Salvador Mérida Donoso, Francisco Bosch-Morell, Amparo Navea; Bevacizumab lessens inflammation in an acute animal model of endotoxin-induced uveitis. . Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):161.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Bevacizumab is a monoclonal IgG antibody that binds and inhibits all vascular endothelial growth factor isoforms. The aim of this study was to assess the anti-inflammatory efficacy of Bevacizumab in an experimental uveitis model upon a subcutaneous injection of lipopolysaccharide into Lewis rats, a valuable model for ocular acute inflammatory processes.
The integrity of the blood-aqueous barrier was evaluated 24 h after endotoxin-induced uveitis (EIU) by valuing two parameters: cell count and protein concentration in aqueous humors. Enzyme-linked immunosorbent assays of the aqueous humor samples were achieved to measure the levels of the diverse chemokine and cytokine proteins. The histopathology of the ocular was also considered.
The inflammation observed in the anterior chamber of the eyes when Bevacizumab was administered with endotoxin was largely prevented since the aqueous humor cell infiltration substantially lowered concomitantly with a significant reduction in the uveal and vitreous histopathological grading. Th1 lymphocytes-related cytokine, Interleukin-2 values was also significantly reduced (Endotoxin group: 791,6 ± 250,9 pg/ml; Bevacizumab treated group: 303,7 ± 59,7 pg/ml; p ≤ 0.05), while protective IL-6 (Endotoxin group: 1285,0 ± 396,5 pg/ml; Bevacizumab treated group: 5205,8 ± 1412,0 pg/ml; p ≤ 0.05) and IL-10 (Endotoxin group: 208,0 ± 84,5 pg/ml; Bevacizumab treated group: 348,1 ± 160,0 pg/ml; p ≤ 0.05) cytokines values were increased. Concurrently, some related M1 macrophages chemokines displayed relevant increases, including GRO/KC (Endotoxin group: 3180,3 ± 1134,5 pg/ml; Bevacizumab treated group: 11911,1 ± 2063,7 pg/ml; p ≤ 0.05) a chemokine that could play any kind of protective role too.
At 24 h post-administration, Bevacizumab treatment in EIU significantly prevented the inflammation observed in the anterior chamber of the eyes since a substantial reduction was observed in cellular infiltration, concomitant with significant reduction noted in the uveal and vitreous histopathological grading. Bevacizumab treatment also reduced Th1 lymphocytes-related cytokine Interleukin-2 by around 60-70% and increased protective IL-6 and IL-10 cytokines.
This PDF is available to Subscribers Only